Aptevo Therapeutics Inc. (APVO) News
Track canonical SquawkNews coverage tagged to APVO, Aptevo Therapeutics Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 14 indexed stories across 9 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Aptevo Advances APVO451 toward IND-enabling Studies, Optimizes Scalable Manufacturing
Aptevo is optimizing trispecific candidates for scalable manufacturing and expects IND-enabling studies for lead candidate APVO451 in 1H2027.Key Highlights:Original SEC Filing: Aptevo Therapeutics Inc. [ APVO ] - 8-K - S
REGULATION | Sep 24, 2026, 01:05 PM UTC
L
Aptevo Therapeutics Inc. (APVO) Targets IND-Enabling Studies for APVO451 in 1H2027
Aptevo Therapeutics said it is optimizing trispecific candidates for scalable manufacturing and expects to begin IND—enabling studies for lead candidate APVO451 in 1H2027.Material DetailsContext by AI AnalystThis is an e
NEWS | Sep 24, 2026, 12:13 PM UTC
L
Aptevo Advances Next-Generation Trispecific Candidate Toward Clinical Development
Company Making Critical Progress in Scalable Manufacturing and Preparing the Lead Trispecific Candidate for Future Human TestingTrispecifics Combine Three Complementary Cancer-Fighting Functions in One Molecule, Enabling
NEWS | Sep 24, 2026, 12:11 PM UTC
L
APVO - Aptevo Advances Next-Generation Trispecific Candidate Toward Clinical Development
APVO - Aptevo Advances Next-Generation Trispecific Candidate Toward Clinical Development
NEWS | Sep 24, 2026, 12:05 PM UTC
M
Aptevo reports 93% clinical benefit rate in frontline AML
Aptevo reported a 93% clinical benefit rate for mipletamig with venetoclax and azacitidine in evaluable frontline TP53-mutated AML patients.
CENTRAL_BANK | Sep 03, 2026, 12:24 PM UTC
M
Aptevo reports 93% clinical benefit rate with mipletamig triplet
Aptevo Therapeutics said mipletamig triplet produced a 93% clinical benefit rate in difficult-to-treat TP53-mutated frontline AML, with remission results described as nearly doubling published ven/aza outcomes.
CENTRAL_BANK | Sep 03, 2026, 12:05 PM UTC
M
Aptevo reports 93% clinical benefit rate in TP53-mutated AML
Aptevo says mipletamig triplet delivered a 93% clinical benefit rate in difficult-to-treat TP53-mutated frontline AML.
CENTRAL_BANK | Sep 03, 2026, 12:05 PM UTC
L
Aptevo files S-1 for up to 6.44 million share issuance
APVO files a Form S-1 covering up to 6,444,858 shares of common stock issuable upon exercise of pre-funded warrants, common warrants and inducement warrants.
REGULATION | Aug 21, 2026, 08:11 PM UTC
L
Aptevo (APVO) reports 2Q26 results and provides business update
Aptevo (APVO) issues a 2Q26 business update and reports second-quarter financial results, per the TradeXchange Newsdesk wire.
EARNINGS | Aug 14, 2026, 12:05 PM UTC
H
Aptevo Therapeutics closes warrants exercise and PIPE for $4.5M
Aptevo Therapeutics (APVO) announces the closing of existing warrants exercise and a PIPE raising $4.5 million in gross proceeds.
MNA | Aug 13, 2026, 08:05 PM UTC
L
APVO Raises $4.5 Million
Aptevo Therapeutics announces exercise of existing warrants and PIPE for $4.5 million gross proceeds
EQUITY | Aug 12, 2026, 01:33 PM UTC
L
APVO Aptevo Therapeutics - announces new solid tumor strategy - SEC filing - Files patent application for nectin-4 X pd-l1 dual-targeting ba
APVO Aptevo Therapeutics - announces new solid tumor strategy - SEC filing - Files patent application for nectin-4 X pd-l1 dual-targeting backbone - SEC filing
REGULATION | Jul 27, 2026, 08:14 PM UTC
H
Why Ultra Clean Shares Are Trading Higher By Over 6%; Here Are 20 Stocks Moving Premarket
Shares of Ultra Clean Holdings Inc (NASDAQ: UCTT ) rose sharply in pre-market trading after the company announced the appointment of Michael Keogh as CFO. The company appoints Michael Keogh as CFO, effective Aug. 25, suc
EARNINGS | Jul 09, 2026, 08:53 AM UTC
L
Andy Hill Cancer Research Endowment Awards Aptevo Therapeutics $1.5M Non-Dilutive Research Grant For APVO451.
Andy Hill Cancer Research Endowment Awards Aptevo Therapeutics $1.5M Non-Dilutive Research Grant For APVO451.
EQUITY | Jun 30, 2026, 12:15 PM UTC